AG真人官方

Standard BioTools (LAB) filed a Form 4 reporting that President & CEO Michael Egholm was granted 3,000,000 Restricted Stock Units (RSUs) on 01-Aug-2025 at no cost (Transaction Code 鈥淎鈥�). Vesting is service-based: 25 % vests on 01-Aug-2026 and the remaining 75 % vests in three equal annual installments through 2029. Following the award, Egholm鈥檚 direct beneficial ownership rises to 5,736,285 shares, which includes 5,000 shares previously acquired via the company鈥檚 Employee Stock Purchase Plan. No shares were sold and no derivative transactions were reported, making the filing a pure incentive grant. While the award strengthens management鈥搒hareholder alignment over the long term, settlement of the RSUs will add to the share count and could be dilutive once the units convert to common stock.

On 29 Jul 2025, Standard BioTools Inc. (LAB) filed an 8-K disclosing new executive retention incentives.

• CEO Michael Egholm is granted 3,000,000 RSUs: 25 % vests 1 Aug 2026; the remaining 75 % vests in three equal annual tranches thereafter, subject to continuous service.
• CFO Alex Kim is granted 1,500,000 RSUs: 40 % vests 20 Jul 2026 and 60 % vests 20 Jul 2027.
• Grants are issued under the amended 2011 Equity Incentive Plan and governed by the 2023/2024 Change-of-Control & Severance Plans.
• The Human Capital Committee also raised Mr. Kim鈥檚 annual cash bonus target to 80 % of base salary, retroactive to 1 Jan 2025.

No operating or financial results accompanied the filing. While the equity awards strengthen leadership retention, they add share-based compensation expense and create potential dilution for existing shareholders.

Standard BioTools Inc. (LAB) 鈥� Form 4/A (filed 07/30/25)

Director Troy Cox filed an amended Form 4 to correct the share count shown in Column 5 of Table I of the original filing dated 06/24/25. After the correction, Cox is shown as beneficially owning 319,322 shares of LAB common stock. No new acquisitions, dispositions, option exercises, or derivative positions are reported; the filing strictly updates the post-transaction ownership figure. All other data from the original Form 4 remain unchanged. Because the amendment merely revises record-keeping and does not reflect a new transaction, the disclosure is administrative in nature and has negligible economic impact on shareholder value or float.

Standard BioTools (NASDAQ:LAB) submitted a routine Form 4 disclosing director Troy Cox received 94,592 restricted stock units (RSUs) that vest in full by June 20 2026 and a stock option for 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly installments beginning July 20 2025.

Following these grants, Cox鈥檚 beneficial ownership stands at 256,412 common shares. No shares were sold, and the filing contains no additional transactions or financial disclosures.

Standard BioTools Inc. (LAB) has reported insider equity awards to Director Fenel M. Eloi on Form 4 dated 06/24/2025. On 06/20/2025 Eloi received 94,592 Restricted Stock Units (RSUs) valued at $0 per unit and 125,660 non-qualified stock options with an exercise price of $1.05 per share. The RSUs vest in full on the earlier of 20 June 2026 or one day before the next annual meeting, while the options vest in twelve equal monthly tranches beginning 20 July 2025 and expire 20 June 2035.

After these grants, Eloi鈥檚 direct holdings increase to 236,183 common shares and 125,660 options. The transaction code 鈥淎鈥� indicates the shares and options were awarded by the company rather than purchased on the open market. No Rule 10b5-1 trading plan was noted, and the filing concerns routine director compensation rather than open-market buying or selling.

Standard BioTools Inc. (LAB) 鈥� Form 4 insider transaction filed 06/24/2025

Director Thomas D. Carey reported two equity awards dated 06/20/2025:

• 94,592 Restricted Stock Units (RSUs) that vest in full on the earlier of 20 Jun 2026 or one day prior to the company鈥檚 next annual meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting.
• 188,490 stock options with a $1.05 exercise price, becoming exercisable in 12 equal monthly installments beginning 20 Jul 2025 and expiring 20 Jun 2035, also subject to continued service.

Following these grants, Carey鈥檚 direct beneficial ownership stands at 194,058 common shares. No dispositions were reported; the grants were acquired at $0 cost (for RSUs) and standard option pricing applies upon exercise. The filing does not reference any 10b5-1 trading plan.

The reported awards reflect routine director compensation and do not involve open-market purchases or sales; therefore, immediate dilution or cash impact to shareholders is negligible. Investors may view the transaction primarily as a governance disclosure rather than a signal of near-term fundamentals.

Standard BioTools Inc. (LAB) Form 4 filing dated 06/24/2025 details new equity awards granted to director and 鈮�10% shareholder Eli Casdin.

• Restricted Stock Units (RSUs): 94,592 RSUs awarded on 06/20/2025; they vest in full on the earlier of 06/20/2026 or one day prior to the next annual meeting, conditional on continued service. Each RSU converts into one common share.
• Stock Options: Option covering 125,660 shares with a $1.05 exercise price, granted 06/20/2025. The option vests in 12 equal monthly installments beginning 07/20/2025 and expires 06/20/2035.
• Post-transaction ownership: 2,901,062 shares held directly. Through affiliated investment funds, Casdin controls an additional 76,075,636 shares (13,939,637 via Casdin Private Growth Equity Fund II, 2,744,219 via Casdin Private Growth Equity Fund, and 59,391,780 via Casdin Partners Master Fund).
• Role: Casdin is both a director and 鈮�10% beneficial owner, indicating significant ongoing influence.

No purchase or sale of shares occurred; the awards were granted at no cost, reflecting routine director compensation and aligning incentives with shareholders. The filing does not disclose any earnings data, cash consideration, or changes to company guidance.

Standard BioTools (NASDAQ:LAB) filed a Form 4 disclosing equity awards to director Kathy L. Hibbs executed on 20 Jun 2025.

The filing reports the grant of 94,592 restricted stock units (RSUs) that vest in full on 20 Jun 2026 or one day before the next annual shareholders鈥� meeting, contingent on continued service. Following the award, Hibbs鈥� direct ownership increased to 137,720 common shares.

In addition, Hibbs received a stock option for 125,660 shares exercisable at $1.05 per share. The option vests in twelve equal monthly instalments starting 20 Jul 2025 and expires 20 Jun 2035.

No shares were sold; all reported transactions were acquisitions recorded under direct ownership. The activity appears to reflect routine director compensation rather than open-market buying.

Form 4 filing for Standard BioTools Inc. (LAB) dated 24 June 2025 discloses equity compensation granted to board member Frank Witney on 20 June 2025.

Restricted Stock Units (RSUs): Witney received 94,592 RSUs at no cost. The award vests in full on the earlier of 20 June 2026 or one day prior to the company鈥檚 next annual shareholder meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting. After the grant, the director鈥檚 direct holdings rise to 210,862 shares; an additional 4,225 shares are held indirectly through a family trust.

Stock Option: He also received a non-qualified option for 125,660 shares with a strike price of $1.05. The option vests in twelve equal monthly installments starting 20 July 2025 and expires 20 June 2035. The filing reports no disposals and no cash paid for the RSUs; any cash impact would occur only if the option is exercised.

The transaction reflects a routine, service-based compensation grant rather than an open-market purchase, aligning director incentives with shareholder value but producing no immediate effect on cash flow or operations. If fully vested and exercised, the awards could increase the company鈥檚 outstanding share count by up to 220,252 shares, but the filing provides no data to assess relative dilution.